Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market

MUSL · Price

Executive Summary

  • Promino Nutritional Sciences announced the planned launch of its first Muscle Health Research Initiative, marking a strategic step toward generating proprietary human evidence for its product portfolio.
  • The initiative centers on an 8-week real-world evaluation study of its flagship product, Rejuvenate Muscle Health™, targeting approximately 50 adults currently using GLP-1 weight management therapies.
  • The study aims to assess product adherence, functional muscle-health metrics, nutritional intake, and participant-reported outcomes, with results intended to support expansion into weight management, healthy aging, and sports performance markets.

Key Details

  • Study Scope: First Muscle Health Research Initiative; real-world evaluation study.
  • Product Tested: Rejuvenate Muscle Health™ (flagship brand, available at www.drinkrej.com).
  • Target Cohort: Approximately 50 adults currently prescribed GLP-1 medications under physician-supervised weight management programs.
  • Study Duration: 8 weeks.
  • Assessment Metrics: Product adherence, functional muscle-health measures, nutritional intake patterns, and participant-reported outcomes.
  • Execution Partner: To be conducted in collaboration with an independent research or clinical partner.
  • Strategic Objective: Generate proprietary human evidence to support the broader muscle health platform across weight management, healthy aging, active lifestyle, and sports performance segments.
  • Product Portfolio Context: Platform includes Rejuvenate Muscle Health™ (everyday consumers) and Promino™ NSF Certified for Sport® (athletes/performance-focused individuals).
  • Future Reporting: Company expects to provide periodic updates on study initiation, enrollment progress, and completion.

Notable Quotes

  • Vito Sanzone, CEO: "The rapid adoption of GLP-1 therapies has increased awareness around the importance of maintaining muscle health and adequate nutrition during weight-loss programs. Our objective is to build a leading proprietary muscle health platform supported by differentiated formulations, commercial execution and scientific evidence. Rejuvenate Muscle Health™ is the cornerstone of that strategy, and this initiative is designed to generate real-world insights that support the continued development of the brand and our broader muscle health platform."
Read the original news release →

More from Promino Nutritional Sciences Inc